ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

radiprodil

Also written as “Radiprodil”, “RGH-896” and “Radiprodil with Carbamazepine”.

Its studies are mostly in Tuberous Sclerosis · Neurodevelopmental Disorders · Spasms, Infantile · Pain, led by 3 companies.

Drug pageRadiprodil: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 31, 202510 company-led studies, 5 open or runningNext primary completion: Nov 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GRIN Therapeuticsits history only75 open or runningphase 3since Oct 31, 2025Feb 22, 2023Nov 2026phase 1 · NCT05818943
UCBits history only20 open or runningphase 2since Jul 8, 2016Jan 4, 2016none ahead
AbbVieits history only10 open or runningphase 2since Feb 5, 2009Feb 5, 2009none ahead

Also a collaborator on its studies: Angelini Pharma, Avance Clinical Pty, PRA Health Sciences and Gedeon Richter.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 5, 2009First study: phase 2 study in PainNew to AbbVieAbbVie · NCT00838799 · 458 enrolled · United States
  2. Jan 4, 2016UCB’s first study: phase 1 study in Healthy VolunteersNew to UCBUCB · NCT02647697 · 10 enrolled · Netherlands
  3. Jul 8, 2016Phase 2 study in Spasms, InfantileUCB · NCT02829827 · 3 enrolled · France
  4. Feb 22, 2023GRIN Therapeutics’ first study: phase 1 study in GRIN-related DisordersNew to GRIN TherapeuticsGRIN Therapeutics · NCT05818943 · 24 enrolled · United States, Australia, Canada and more
  5. Apr 23, 2024Phase 2 study in Tuberous SclerosisGRIN Therapeutics · NCT06392009 · 30 enrolled · Australia, Belgium, Canada and more
  6. Apr 11, 20252 phase 1 studies in Tuberous SclerosisGRIN Therapeutics · NCT06975605, NCT06965881
  7. Oct 31, 2025Phase 3 study in GRIN-related Neurodevelopmental DisorderGRIN Therapeutics · NCT07224581 · 100 planned · United States, Australia, Belgium and more
  8. Feb 26, 2026Phase 1 study in Hepatic ImpairmentGRIN Therapeutics · NCT07457229 · 40 planned · United States
  9. Nov 5, 2026Phase 1 study in GRIN-related Neurodevelopmental Disorder Caused by Variants Characterized as Non-Gain-of-FunctionGRIN Therapeutics · NCT07941206 · 27 planned

Ahead

  1. Nov 2026Primary completion: phase 1 study in GRIN-related DisordersGRIN Therapeutics · NCT05818943
  2. May 2027Primary completion: phase 1 study in Hepatic ImpairmentGRIN Therapeutics · NCT07457229
  3. May 2027Primary completion: phase 3 study in GRIN-related Neurodevelopmental DisorderGRIN Therapeutics · NCT07224581
  4. Oct 2027Primary completion: phase 1 study in GRIN-related Neurodevelopmental Disorder Caused by Variants Characterized as Non-Gain-of-FunctionGRIN Therapeutics · NCT07941206

TargetBeta

“Glutamate NMDA receptor; GRIN1/GRIN2B antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
EsketamineruleJohnson & Johnsonphase 451
MemantineruleAbbViephase 429

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07941206GRIN-related Neurodevelopmental Disorder Caused by Variants Characterized as Non-Gain-of-Function1Not yet recruitingGRIN TherapeuticsOct 202727
NCT07457229Hepatic Impairment · United States1RecruitingGRIN TherapeuticsMay 202740
NCT07224581GRIN-related Neurodevelopmental Disorder · United States, Australia, Belgium and more3RecruitingGRIN TherapeuticsMay 2027100
NCT06975605Tuberous Sclerosis · Australia1CompletedGRIN TherapeuticsJul 10, 202518
NCT06965881Tuberous Sclerosis · Australia1TerminatedGRIN TherapeuticsJul 8, 202530
NCT06392009Tuberous Sclerosis · Australia, Belgium, Canada and more2Active, not recruitingGRIN TherapeuticsJun 202630
NCT05818943GRIN-related Disorders · United States, Australia, Canada and more1Active, not recruitingGRIN TherapeuticsNov 202624
NCT02829827Spasms, Infantile · France2TerminatedUCBOct 2, 20183
NCT02647697Healthy Volunteers · Netherlands1CompletedUCBFeb 201610
NCT00838799Pain · United States2CompletedAbbVieApr 2010458

How it is read

Names in the registry

  • “Radiprodil”, 6 entries
  • “RGH-896”, 3 entries
  • “Radiprodil with Carbamazepine”, 1 entry
  • “Radiprodil with Itraconazole”, 1 entry
  • “Radiprodil + co-administered drugs”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.